๐๏ธ Verified NIH Record โข Updated 2026-08-10
Group-based Comprehensive Lifestyle Program for Women With Metastatic Breast Cancer (NCT07179809)
Pilot Randomized Trial of a Virtual, Group-based Comprehensive Lifestyle Program for Women With Metastatic Breast Cancer: Exploring Dose of Support to Optimize Adherence
๐ก Not Yet Recruiting Observational / Diagnostic ๐ Clinical Research Protocol Sponsor: M.D. Anderson Cancer Center
๐ฉบ Plain-English Summary (8th-Grade Level)
The research study is to learn how the ACLP can best support patients with stable HR+/HER2- MBC.
Who can join: Review the eligibility criteria below.
Location: The University of Texas M. D. Anderson Cancer Center โ Houston, Texas
Age range: 18 Years
๐งช Interventions in This Study
- Demographics/Lifestyle Survey (OTHER)
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (1 Sites)
- The University of Texas M. D. Anderson Cancer Center โ Houston, Texas
๐ Contact the Study Coordinator
Phone: (713) 794-4053
Email: mbmorse@mdanderson.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Breast Cancer
- Assessing the Time Demands of Cancer โ Birmingham, Alabama
- Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer โ Birmingham, Alabama
- A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer โ Commack, New York
- Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor โ Washington D.C., District of Columbia
- A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer โ Tucson, Arizona
- Roll-over Study to Allow Continued Access to Ribociclib โ Chandler, Arizona
Explore by condition: All Metastatic Breast Cancer clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.